An ongoing phase I/II trial is currently evaluating this TRuC chimeric switch receptor in individuals with 1+, 2+, or 3+ mesothelin expression in at least 50% of tumor cells by IHC (NCT05451849) [81]. The gene discussed is MSLN; the disease is neoplasm.